Overview

Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

Status:
Active, not recruiting

Trial end date:
2022-09-28

Target enrollment:

Participant gender:

Summary

This is a Phase 1b open-label study to evaluate the safety and clinical activity of zimberelimab (AB122) in biomarker-selected participants with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Arcus Biosciences, Inc.

Collaborator:

Strata Oncology